The conference is over - but here you will find presentations, conference book, news and photos.
Click on the images below to access the gallery...
International Conference on Perspectives in Precision Medicine, 28 February 2018 - 1 March 2018
We are facing a paradigm change in the development of more personalised medicine. Research and commercial development in the cross field between public health, health records, biobanks, biomarkers, information and communication technologies, user perspectives and the established fields of the pharmaceutical industry are emerging growth areas.
This International Conference on Perspectives in Precision Medicine will focus on possibilities and challenges in the cross field between pharmaceutical development, user involvement and Information and Communications Technology (ICT). The conference will introduce new cross-disciplinary research fields and bring together key stakeholders and experts in the three converging disciplines: pharmaceutical development, user involvement and ICT. The event will include keynote speakers, panel discussions, thematic round tables, site visits and relevant matchmaking activities, which hopefully can lead to new fruitful partnerships. Everyone with an interest in precision medicine, especially in the cross field between pharmaceutical development, user involvement and ICT, are welcome to attend the conference.
The conference especially targets SMEs, researchers and anyone else who are looking into new insight and knowledge on personalised medicine, want to discover new business and research opportunities, meet potential partners, expand their network, and be inspired by a world leading pharmaceutical hub in the heart of Copenhagen.
Share your experience on social media: #precmedcph18
Welcome speech presentation
Keynote speaker presentations
Site visit presentation
Summary of Round Table discussions
Click to read Background and Summary of Round Table discussions
Wednesday 28 February 2018 (Day 1)
11:30 Arrival, registration and lunch + foyer funding exhibition
12:30 Opening session
- Conference moderator - Nynne Bjerre Christensen, Journalist
- Agnete Gersing, Permanent Secretary, Danish Ministry of Higher Education and Science
- Ulla Wewer, Dean, Professor, Faculty of Health and Medical Sciences, University of Copenhagen
- Per Spindler, Director, Biopeople – Denmark’s Life Science Cluster, University of Copenhagen
13:00-15:20 Key notes
Building an Enterprise Grade Precision Medicine Infrastructure for Healthcare / Jonathan Sheldon, Jonathan Sheldon, Ph.D., is Senior Vice President and member of the Executive Committee at QIAGEN
Precision Medicine and Biomarkers / Nils Brünner, Professor, Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen
Korean Precision Medicine Enterprise – innovative initiative / Yeul Hong Kim, Professor, Korea University College of Medicine Director, Korean Precision Medicine Enterprise
15:20-16:30 Panel discussion led by conference moderator
- Alain Van Gool, Professor of Personalized Health Care, Radboudumc, Head Translational Metabolic Laboratory, Radboud University Medical Center
- Jonathan Sheldon, Jonathan Sheldon, Ph.D., is Senior Vice President and member of the Executive Committee at QIAGEN
- Helle B. Konradsen, Director, MD, Management of the Danish National Biobank, Statens Serum Institut (SSI)
- Nils Brünner, Professor, Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen
- Mette Nordahl Svendsen, Professor mso, Department of Public Health, Section of Health Services Research , University of Copenhagen
- Yeul Hong Kim, Professor, Korea University College of Medicine Director, Korean Precision Medicine Enterprise
16:45-18:15 Match making & foyer funding exhibition - pre-booked meetings
18:15-20:00 Reception & light dinner, Executive Floor of the Maersk Tower, University of Copenhagen
Thursday 1 March 2018 (Day 2)
08:30 Welcome coffee
09:00-10:00 Key notes
Biobanks in Precision Medicine – National strategies / Helle B. Konradsen, Director, MD, Management of the Danish National Biobank, Statens Serum Institut (SSI)
Developing a shared infrastructure for personalised health and medicine research: experience from the Netherlands / Alain Van Gool, Professor of Personalized Health Care, Radboudumc, Head Translational Metabolic Laboratory, Radboud University Medical Center
10:15-10:40 Biomarkers and Personalised Medicine as Emerging Growth Area in Denmark / Kim Holmstroem, Bioneer, The Danish Biomarker Network
10:45-11:40 Round table discussions on challenges and opportunities in the cross field between pharma, ICT and user involvement
11:40-12:00 Summary of round tables discussions
12:00-12:10 Wrap up & farewell
News on conference and speakers
Denmark has a unique international position in addressing the interrelationship between pharmaceutical R&D, ICT and user involvement
- Denmark is home to the most innovative biotech industries in the world and Denmark is ranked as the best country in Europe for development of biotechnology. This includes strong R&D collaborations with Danish universities and research organisations and a high degree of interdisciplinary involvement.
- The Danish biotech industry comprises more than 160 companies, employs approximately 40,000 people, including more than 5,000 dedicated R&D employees. Together with the 8 universities, 7 science parks and 4 major university hospitals this makes a unique platform.
- In 2017, Denmark launched a national strategy on Personalised Medicine based on a yearlong systematic collection of data and knowledge about the Danish population’s diseases and treatment. In relation to this, Denmark opened their first National Genome Center, which will unfold the potential of personalised medicine.
- Denmark is a highly developed ICT nation and as such has a unique and strong environment for developing ICT solutions, which address health related needs and challenges.
- The Danish digital eco system has a strong technological foundation for system development integrating hardware and software and it comprises one of the most competitive and advanced telecommunications infrastructure and mobile markets. This in particular will be central for the development of new smart products for applications in health.
- User involvement in health care has become an important focus area in Denmark in relation to safety issues, self-care, partnerships in biomedical R&D and others. Patients are already involved in many ways, however, both ICT and pharmaceutical research & development could benefit even more from partnering with "users" and patients.